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ABSTRACT 
 Hydrogen sulfide (H2S) produced in the reverse transsulfuration pathway is a 
significant signaling molecule. The two known pyridoxal-5'-phosphate (PLP)-dependent 
enzymes that catalyze H2S generation in mammals are cystathionine β-synthase (CBS) and 
cystathionine γ-lyase (CSE). The interaction between H2S/CSE and NO/NOS systems, 
which have regulatory roles, has been recently discovered in mice. To study the effects of 
signaling molecules NOx on human recombinant cystathionine γ-lyase, recombinant CSE 
was incubated in the presence of low or high oxygen contents with NO donors 
diethylamine NONOate (DEANO) and S-Nitrosoglutathione (GSNO). The enzyme was 
then tested for H2S production upon incubation with the CSE substrate, L-cysteine. A 
novel, real-time H2S detection method using H2S-permeable polydimethylsiloxane 
(PDMS) and thiol-reactive probe, Ellman's reagent, was utilized for enzyme activity 
measurement. These experiments reveal that the catalytic efficiency, Kcat/KM, of substrate 
was found to be significantly affected by NO incubation. NO incubation decreased the 
enzyme activity by lowering the binding affinity of the substrate to the enzyme. At 2 ppm 
or 16 ppm oxygen concentration, NO released from NO donor was proposed to directly 
modify protein residues such as cysteine, tryptophan and tyrosine. In addition, inhibition 
of NO production in RAW 264.7 macrophage can induce H2S production. These studies 
indicate a potential regulatory role of NO in H2S production by either directly reacting 
with H2S or modulating H2S-producing pathways. 
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CHAPTER 1 
GENERAL INTRODUCTION OF H2S 
1.1 General Introduction of H2S 
1.1.1 History of Hydrogen Sulfide and Existing H2S in Physiological 
Environment 
 H2S is known as a toxic gas with an odor resembling that of rotten eggs. It is a 
major component in the origin of life and it continues to be critically important for life on 
earth (1). Naturally occurring H2S is often formed from the breakdown of the organic 
compounds by bacteria in the absence of oxygen. The first record observation of H2S was 
in 1713. An Italian physician described in his book, Disease of workers, that workers 
who were exposed to an unknown acid had painful inflammation around their eyes. Later 
around 1750, a Swedish chemist accidentally mixed potassium ferrous sulfide with a 
mineral acid, forming a malodorous gas. This was the first occasion H2S had been 
synthesized. In the 20
th
 century, investigations on the biological effects of H2S began (2). 
In the past H2S was most recognized for its toxicity which has been found to be 
achieved via its inhibitory interaction with hemoglobin and cytochrome c oxidase. To 
effect inhibition, the HS
-
 anion binds to ferric heme in cytochrome c oxidase. The 
blockage of mitochondrial cytochrome c oxidase by H2S is believed to be the mechanism 
involved in lethal sulfide poisonings. This inhibition results in decreased oxidative 
phosphorylation, which will in turn lower the metabolic rate and body temperature, 
resulting in hypothermia (2). In contrast, physiological H2S concentrations actually 
facilitate mitochondrial consumption and ATP production (3). The American conference 
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of Industrial Hygienists has set up a standard for the exposure limitation, called a 
threshold limit value (TLV). In the workplace, the H2S TLV is 10ppm in air for 8 h a day, 
five days a week over a working lifetime (2).  
1.1.2 Physical properties and solubility of H2S 
 Similar to other gaseous molecules, H2S is lipophilic and freely penetrates plasma 
membranes. This is a very important property because it determines the traveling route 
and the extent of H2S action. H2S is twice as soluble in lipid membrane as in water. This 
high membrane permeability coefficient of H2S displays a low barrier to intercellular 
transport.  
 In a physiological environment, H2S is usually referred to as the total free sulfide 
pool of H2S, HS
-
 and S
-
. H2S is a weak acid with pKa1 6.9 and pKa2 11.96, and will 
dissociate to HS
-
 and S
-
 (Scheme 1) (4). At a pH of 7.4, the ratio of HS
-
:H2S is 1:3. At 
physiological pH, H2S which is in the form of hydrosulfide accumulates near its source, 
due to the low diffusion rate resisted by lipid membrane (5). Free H2S (H2S + HS
-
) 
concentration in humans varies. The concentration of total H2S is estimated around 100 
pM in blood, and15 nM in tissue (6).  
 
 
Scheme 1: H2S dissociation in aquesous solution 
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1.1.3 H2S as a gasotransmitter 
 Recently, H2S has been recognized as a common component of mammalian 
tissues and cells; an interesting finding considering the longstanding reputation of H2S 
as a highly toxic compound. It may be important for homeostatic control and functions 
similar to other toxic gases including nitric oxide (NO) and carbon monoxide (CO) that 
also function as gasotransmitters. After careful consideration, H2S was deemed to 
fulfill all of the criteria that define a gasotransmitter (7). The term gasotransmitter 
refers to a gaseous molecule that is synthesized and released in a biological system and 
has a signal transduction function. The following are identification criteria for 
gasotransmitters. It must 
1. be a gas 
2. be endogenously and enzymatically generated in a regulated manner 
3. cause, upon exogenous application, well-defined physiological effects at relevant 
concentrations that mimic the effect of the endogenously produced H2S on tissue 
activity 
4. act on specific cellular targets  
5. use a specific mechanism of inactivation (8). 
 According to the definition, H2S is a small gaseous molecule that is able to cross 
the lipid membrane. Since H2S is highly permeable in lipids and can penetrate cellular 
membranes, it is a good signaling molecule (9). It is enzymatically synthesized and its 
endogenous metabolism is tightly regulated. The cellular effects of H2S do not need 
second messenger or specific cognate membrane receptors, but it triggers defined 
signaling cascades directly (3).  
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Specific cellular targets of H2S: Several reported receptors are found to be tissue- and 
species-dependent. For example, H2S activates glutamate receptors during repetitive 
nerve stimulation via cAMP-dependent pathways, by opening several ion channels. 
(8,10,11).  
As a result, H2S has been identified as the third signaling gasotransmitter after NO and 
CO. Now, researchers are trying to determine the regulatory functions of H2S by 
comparing it to the functions of NO and CO, as well as exploring the interactions 
between these three gasotransmitters (12,13). 
1.1.4 H2S in the biological system 
 A number of organisms have been shown to have the ability to produce and utilize 
H2S (13). In animals, the highest production rate of H2S was found in the brain, 
cardiovascular system, liver and kidney (14). The two known existing enzymes that can 
catalyze H2S production in mammals are cystathionine β-synthase (CBS; EC 4.2.1.22) 
and cystathionine γ-lyase (CSE; EC 4.4.1.1). These two enzymes are involved in the H2S 
production in the transsulfuration pathway. A third source of H2S production is through 
the enzyme pair, 3-mercaptopyruvate sulfurtransferase and cysteine aminotransferase, 
through the catalysis transfer of sulfur to an unknown acceptor. This third source of H2S 
generation is also known as cysteine catabolism (4). This H2S production pathway is 
regulated by Ca
2+
 and facilitated by thioredoxin and dihydrolipoic acid (15). The relative 
contribution of the third source of H2S to signaling events are largely unknown (12). A 
minor component of H2S in biological environment is produced nonenzymatically from 
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the reduction of elemental sulfur to H2S using reducing equivalents obtained from the 
oxidation of glucose (16). 
 CBS is essentially responsible for the H2S production in the central nervous 
system. In comparison, CSE chiefly generates H2S outside of the cardiovascular system 
(13). MST is expressed in kidney, liver, cardiac tissue and in the brain (17). CBS and 
CSE are expressed in the cytoplasm, but have also been detected in the nucleus (4).  
1.1.5 Transsulfuration and Reverse Transsulfuration of H2S Production   
Transsulfuration and reverse transsulfuration are the two alternate pathways for 
interconverting methionine and cysteine (18) (Figure 1.1). The reverse transsulfuration 
pathway normally takes place in mammals. This pathway involved in two major 
enzymes: CBS and CSE (19). Transulfuration has the following steps. Serine and 
homocysteine formed from the methionine pathway would be catalyzed by CBS. The 
cystathionine produced by CBS will subsequently catalyzed by CSE to form cysteine (3). 
The resulting cysteine further undergoes cysteine catabolism to produce pyruvate and 
NH3. In addition, CBS and CSE catalyze several reactions to produce H2S, and other side 
products such as lanthionine, α-ketobutyrate, pyruvate as well as cystathionine. CBS 
pariticipates in four major reactions which involve the β-carbon of cysteine (20). The 
chief route responsible for H2S production is the condensation of homocysteine and 
cysteine. H2S cannot be formed by homocysteine alone catalyzed by CBS (12). CSE 
catalyzes six H2S-producing reactions which include α,β–elimination, β–replacement, α,γ 
– elimination, β or γ–replacement using cysteine and homocysteine (12). The major 
substrate responsible for H2S production by CSE is cysteine (4). 
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 The transsulfuration pathway is the reverse pathway of reverse transsulfuration. 
The H2S biosynthesis pathways occur in prokaryotes, fungi, and plants. Cystathionine γ-
synthase (CGS) and cystathionine β-lyase (CBL) are the two enzymes involved in this 
pathway (3).  
 
Figure 1.1 Transsulfuration pathway. The top part depicts the transsulfuration pathway. 
CBS and CSE are involved in this pathway. The red arrows indicate the major H2S 
production reaction for CBS and CSE (4). 
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1.1.6 H2S Catabolism 
 Labeling with [
35
S] sulfide was used as the earliest method to track the route taken 
by H2S once it is produced. This labeling allowed the biochemists to determine that 
metabolized H2S is located in mitochondria (4). Currently, there are two known H2S 
catabolism pathways. The most common pathway is the oxidation of H2S in mitochondria 
to produce persulfide, sulfite, thiolsulfate and sulfate. Some of these converting reactions 
are enzyme-dependent and some are not (4,14). 
1.1.7 H2S Measurement 
 With increasing knowledge of H2S, an accurate and reliable method of measuring 
H2S is an essential factor to determine its critical biological activities (21). H2S exists in 
several ionic states associated with different environments. The stability is also 
influenced by different inorganic and organic compounds present in biological 
environments. These determinants make it difficult to make accurate measurements of 
H2S. Several methods for measuring free H2S are based on its derivatization to generate 
products for measurement by UV/Vis and fluorescence spectroscopy, or ion-specific 
electrodes (22-24). Many existing methods have been criticized for their overestimation 
of the concentration of H2S in biological systems. Most of these methods rely on 
conversion of all sulfide species to H2S or S
2-
 under acidic or alkaline conditions and 
their indirect detection by trapping with metal ions to form stable, insoluble complexes. 
One of the most widely used methods is the methylene blue (MB) assay, where H2S is 
reacted with N,N-dimethyl-p-phenylenediamine and ferric chloride in a strong acid 
solution. The product methylene blue can be quantified with spetrophotometric analysis 
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(8) (Scheme 2). The disadvantages of the methylene blue assay are that  the wavelength 
of the blue color formed by sulfide can be interfered with other coloured compounds, and 
artificial acidification would shift the equilibrium to favour the gas phase of H2S, and 
therefore underestimate the actual sulfide concentration due to loss of H2S to the 
atmosphere (8). A Recently published assay using fluorimetric, reverse-phase (RP)-
HPLC has gone a long way in eliminating the interferences encountered with the 
methylene blue assay (21). Although this method solves the detection limitation and 
interference issue, it is not able to provide continuous measurement. Among all these 
methods, the putatively most accurate and reliable method is gas chromatography. Even 
though this method has a high reputation for accuracy, the method of collecting minute 
volumes of the gas samples from biological fluids results in large sample losses due to 
the rapid degradation and high liability of H2S (8). Additionally, some other methods fail 
to report the sensitivity of the assay and/or controls for background interference (4). For 
example, some methods use cysteine, the substrate of the enzymes to stimulate H2S 
generation, but the additional cysteine was not subtracted from the result. In summary, 
there is an urgent need for the accurate and specific detection of H2S. The ideal H2S 
detector should be able to measure H2S continuously without contamination from other 
biological thiols, and the detection limit should be sensitive at biological concentration 
(25). Most importantly, the sensor should be cheap and readily available.  
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Scheme 2: Sulfide reacts with N,N-dimethyl-p-phenylenediamine forming a blue 
chromophore 
 
 
 
 
1.2 Sources of H2S in biological systems 
1.2.1 Enzymes that catalyze the formation of H2S: CSE 
 The PLP–dependence of CSE is conserved in various organisms. There are two 
isoforms of human CSE. The internal deletion of 132 base pairs from the long isoform 
forms the short isoform (26). Naturally occurring mutations were also discovered for 
CSE, which are T67I and Q240E (27). These two types of CSE mutations are found 
associated with cystathioninuria. Both mutations reduce the enzymatic activities in 
comparison to the wild-type enzyme, and therefore lead to the accumulation of 
cystathionine. The reduction in activity is attributed to the lower affinity of PLP binding 
(3). A common single nucleotide polymorphism resulting from a replacement of serine at 
position 403 with isoleucine has also been discovered. The natural variant is ethnicity-
dependent and it is thus more obvious in an ethnically diverse country, such as Canada 
(27). Determination of the CSE crystal structure has revealed the active site of CSE as 
well as the CSE protein folding (13). With the binding of PLP, human CSE 
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predominately exists as a tetramer in solution, where each subunit is 44.5 kDa. The 
tetramers are asymmetric in CSE-PLP complex structures (13). Without the binding of 
the PLP cofactor, the two dimers are symmetrically related with each asymmetric unit 
(26). Each individual monomer is assembled by hydrogen bonds and hydrophobic 
interactions to form a tetramer (28). Each CSE monomer contains two domains: a larger 
PLP-binding domain and a smaller domain. The active site (PLP binding site) forms a 
strong hydrogen bond and π–stacking interactions with the prosthetic group PLP (29). 
Observations show that without the binding of PLP, the enzyme can exist in multiple 
conformational states. However, the CSE-PLP tetramer is more stable compared to CSE 
without the binding of PLP (27). Visually, PLP bound CSE has a yellow colour (13).  
 The most common inhibitor of CSE is DL-propargylglycine (PAG) and β-cyano-L-
alanine (β-CNA), where PAG is an irreversible inhibitor and β-CNA is a reversible 
inhibitor (8,30). In detail, the inhibition mechanism of CSE by propargylglycine (PAG) is 
described as the steps of deprotonation of progargyl glycine. Then, the β-position of the 
alkyne is deprotonated to generate an activated alkene. Finally, the vinylether is formed 
by nucleophilic attack (27). As a result of these reactions, the inhibitor occupies the side 
chain of CSE. PAG inhibition essentially blocks the accessibility of the substrate to the 
active site via steric hindrance (13).  
1.2.2 Enzymes that catalyze the formation of H2S: CBS 
 CBS is a homotetramer, composed of four identical subunits. Each subunit has a 
molecular weight of ~63 kDa (31). Human CBS is a dual cofactor-dependent enzyme. 
The cofactors are PLP and heme. Only highly developed animals, such as mammals, 
contain the second cofactor, heme. The heme group is found to reversibly regulate the 
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activity of the enzyme and is redox active (32). It also plays a catalytic role in 
homocysteine-dependent H2S production (32). In recombinant CBS, there are two 
estimated hemes per tetramer (33). The location of the PLP-binding site is confirmed at 
the N-terminus of the protein (33). In addition to the two cofactors, the enzyme binds to 
S-adenosylhomocysteine (AdoMet) at the C-terminal of the enzyme (34).  AdoMet is a 
V-type allosteric effector. The influence of AdoMet is to increase the Vmax, but has no 
effect on the KM of the reaction (32). The biological mechanism of AdoMet binding on 
CBS is, however unknown. The C-terminus of CBS is responsible for the structural 
organization, or, the formation of the tetramer; it also regulates activity of the enzyme 
(32). Human CBS has two repeated CBS domains, which named after the CBS enzyme 
(35). Deletion of the CBS domain was found to increase enzyme activity, and therefore 
the two repeating CBS domains have an inhibitory role on the enzymatic function (36). 
The CBS domain is also proposed to act as an energy sensor for the cellular energy status 
(30). Two commonly used CBS inhibitors are hydroxylamine and aminooxyacetate (9). 
Human CBS can also be inhibited by homocysteine (24).  
1.2.3 MST and CAT 
 The structure of MST (EC 2.8.1.2) is described to have two domains which are 
connected by a linker region. The cofactor of MST is zinc (37). Another enzyme that has 
been reported to be involved in cysteine catabolism is CAT (EC 2.6.1.3) (38). CAT also 
uses PLP as a cofactor (3). The 2- and 3-mercaptopropronic acids are uncompetitive and 
noncompetitive inhibitors of MST (8). Hydrogen peroxide and tetrathionate inhibit MST 
by impeding the catalytic cysteine residue (8). 
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1.2.4 Inhibitors of CSE, CBS as well as MST and CAT 
 Most of these inhibitors mentioned above are general inhibitors rather than 
specific inhibitors to CBS, CSE or MST. For instance, hydroxylamine is a general PLP-
dependent enzyme inhibitor rather than specific inhibitor for H2S enzyme (1). It inhibits 
the enzyme by releasing the cofactor: PLP. Currently, there are no entirely specific CSE 
or CBS inhibitors available. Therefore the experimental results, which use the non-
specific inhibitors for one of these enzymes, should be explained carefully with the 
consideration of other influences of using non-specific inhibitors as the treatment (11). 
The exploration of the enzyme structure is essential for searching for more CSE/CBS-
selective inhibitors. 
1.2.5 Cloning of CBS and CSE  
 In the reverse transsulfuration pathway, CBS catalyzes the first step of the 
pathway (24), and CSE catalyzes the second step in the pathway. Due to the importance 
of these two enzymes in the H2S generating mechanism, research on purification and 
usage of these enzymes have become popular. However, the practice of purifying CBS 
from mammalian tissues is a complicated procedure, due to its susceptibility to 
proteolysis and the tendency to form precipitates (31,39). Therefore, using recombinant 
CBS is a more convenient method to study the enzyme. In addition, CSE purifications 
from different species, such as rats streptomyces, and tissues have been described (15). 
Nonetheless, purification of the enzyme from tissue does not provide a good source for 
obtaining the enzyme. 
 For the purpose of extracting the specific protein from the bacterial cell lysate, an 
affinity tag is normally employed. Tag-fused protein allows for the separation of the 
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protein from crude biological sources using an affinity column. After purification, the 
tags can be cleaved using chemical agents or enzymes. The most widely used tags are 
glutathione-S-transferase (GST) and 6-His tags. GST-fused protein can be purified using 
a column with a high affinity for glutathione. The drawbacks of using GST are the fact 
that GST will leave 11- or 23-residue extensions after the cleavage of the tag (24). In 
contrast, a 6-His tag adds 6 histidine residues to the end of the protein, which can then be 
bound to the affinity media through metal ions (40). The most widely used is the nickel 
column. The protein can be eluted using imidazole buffer. The advantage of using this tag 
is that the removal of the 6-His tag is not required (24). Here, the efficient purifications 
were achieved by obtaining both CBS and CSE. In this purification, his tags were added 
to both terminals of CBS and CSE. 
 
 
 
 
1.3 Functions and related Diseases 
1.3.1 Over-production and under-production of H2S related diseases and functions 
of H2S enzymes in Pathology 
H2S plays important roles in various organ systems including the cardiovascular 
system, nervous system, endocrine system, immune system, respiratory system, 
reproductive system, and urinary system (3). Lower levels of H2S have been implicated 
in the occurrence of Alzheimer’s disease and diabetes in mammals (3,9,41). For instance, 
Alzheimer’s patients, reportedly have attenuated levels of H2S compared with the healthy 
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people (42).  In contrast, high levels of H2S have been implicated in Down syndrome 
(25,43) and cardiovascular disease (33). Specifically, the CBS gene in humans is located 
on chromosome 21, which is the chromosome that is a trisomy in Down syndrome 
sufferers. Therefore, the overproduction of H2S is postulated to have a relationship with 
Down syndrome (14).   
 In the CSE/H2S pathway, Kabil and Banerjee (4) found cystathionase deficiency. 
in CSE knockout mice (4). This sympotom named cystathioninuria, which lead to an 
excess of cystathionine in the urine. Cystathioninuria has also been found associated with 
natural CSE mutations (34). In hyperhomocysteinemic conditions, CSE-related H2S 
generation may be enhanced and it may explain that H2S/CSE is involved in 
cardiovascular pathology (44). Symptoms such as atherosclerosis, myocardial infarction, 
hypertension and shock are linked to the CSE/H2S cardiovascular diseases (14,45,46). 
Defects in CBS gene cause an inherited disorder which can lead to homocystinuria (47) 
which affects major organ systems including cardiovascular, ocular, skeletal and the 
central nervous system (4,48). The homocysteine build up has been implicated in 
coronary and cerebrovascular atherosclerosis (49). Mercapto-lactate-cysteine disulfiduria 
was found related to the deficiency of MST/H2S pathway (50). Since defects of all three 
enzymes involved the accumulation of homocysteine, increased conversion of 
homocysteine to H2S by CBS, CSE and 3MST gene therapy could potentially improve 
these symptoms (28).  
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1.3.2 H2S functions as an Anti-Oxidant 
 H2S functions as an antioxidant in two ways: (1) directly scavenging the reactive 
oxygen species (ROS); (2) reducing glutathione disulfide (51). For instance, elevated 
production of ROS has been found at the location of inflammation (11). In this situation, 
H2S can be used as an agent to facilitate the elimination of ROS. Work has been done by 
supplying homocysteine to check if the stimulated H2S synthesis facilitates the 
antioxidant ability. The results show that high percentages of H2S induce ROS and 
reactive nitrogen species (RNS) production, but low levels of H2S react with H2O2, 
ONOO
-
 , O2˙- (52). In another study, it is proposed that the efficiency of H2S as an 
antioxidant can be improved by combining with certain agents, such as GSH, SOD, L-
NAME or vitamin C (53). This combination hints at a new route for designing novel 
antioxidant and therapeutic drugs. In summary, low H2S may play a beneficial role by 
eliminating ROS and RNS. 
1.3.3 H2S and Inflammation 
 Inflammation is defined as a protective physiological response to local injury and 
tissue damage of vascular tissues (54). There are five clinical conditions including 
redness, heat, swelling, pain and loss of function (11) to describe inflammation. The 
known gas mediators NO and CO have been shown to regulate the inflammatory in the 
biological systems (17). Recently, it has been proposed that H2S has a role in the 
inflammatory process (55,56). During inflammation, the surrounding tissues become 
mildly acidic (11). According to Scheme 1, the locally produced sulfide in the 
inflammation environment would shift the equilibrium towards the formation of H2S. 
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Therefore, H2S rather than other forms of sulfide would likely be found at the site of 
inflammation.  
 H2S is believed to have two contradicting roles in inflammation. It acts as both a 
pro- and anti-inflammatory molecule (9). Li et al. reported that the physiological 
concentration of H2S has anti-inflammatory effects, while higher concentrations of H2S 
can produce pro-inflammatory effects (10). The H2S inflammatory role was also studied 
in different systems. In the gastrointestinal tract, the H2S regulating role functions by 
activating KATP channels in order to promote the inflammation response (57). The similar 
H2S function was observed in pancreas (7), but the actual mechanisms are largely 
unknown. In conclusion, H2S pathway is a possible route for targeting the inflammation 
treatment. However, much work needs to be done for understanding the mechanisms of 
the contradictory roles of H2S in inflammation. 
1.3.4 H2S and Signal Transduction 
 H2S plays several functions in signal transduction mechanisms. It was first 
discovered as a vasorelaxant and a cardioprotective agent (12). Unlike NO, which 
activates the soluble guanylate cyclase/cGMP pathway, H2S-induced vasorelaxation is 
dependent on ATP-regulated potassium channels in vascular smooth muscle cells (14,58). 
In the brain, H2S also can be utilized as a neuromodulator, or to control inflammation, 
regulate insulin release, modulate angiogenesis, and act as a cytoprotectant (9,10,15,24). 
In the gastrointestinal system, H2S may regulate the secretion of bile (59). The reducing 
ability mentioned above makes H2S good candidate as a redox cell signal (50). As with 
inflammation, the mechanisms by which H2S mediates signal transduction are largely 
unknown. 
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1.4 Nitric Oxide 
1.4.1 General Introduction of NO 
 NO, an inorganic molecule plays important regulatory and pathological roles in 
almost all tissues and systems (14). It was the first molecule that was recognized as a 
gasotransmitter, which involves transmitting signal information between cells in various 
tissues. Several important functions of NO are that it serves as a vasodilator (60), an 
inhibitor of various cellular functions (53,61-67), and also functions as a neurotransmitter 
(30). It is biologically synthesized from L-arginine (68) under the catalytic reaction of 
NO synthase (NOS). There are three isoforms of NOS: nNOS, iNOS and eNOS. nNOS 
converts L-arginine to NO and citrulline in the nervous system; eNOS generates NO in 
the vascular system; iNOS is ubiquitously expressed in the body, but most concentrated 
in the cellular immune response, such as macrophages. Calcium-calmodulin activates 
nNOS and eNOS (30) .  
1.4.2 Lipopolysaccharide  
 Lipopolysaccharide (LPS) is a complex glycolipid, which is a major component 
of the outer leaflet of the membrane of Gram-negative bacteria. It protects bacteria from 
host defenses and mediates direct interactions with host cell receptors and antibiotics. As 
an endotoxin, it results in host tissue damage (69). LPS induces iNOS expression as well 
as the production of NO (41) and other pro-inflammatory cytokines (70).   
1.4.3 L-NG-Nitroarginine methyl ester  
 L-N
G
-Nitroarginine methyl ester (L-NAME) (Figure 1.2) has been widely used as 
a competitive inhibitor of NOS (53). The inhibition is due to structural similarities 
between L-NAME and L-arginine (Figure 1.2), the natural substrate of NOS (71), and 
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therefore it blocks the substrate binding site. When L-NAME binds to NOS, the ability 
NOS of converting L-arginine to NO is decreasing. 
 
                                                          
(A) 
 
(B) 
Figure 1.2 Structures of NOS inhibitor L-NAME hydrochloride (A) and arginine (B). 
Structure of L-NAME is similar to arginine. 
 
 
 
1.4.4 NO donors: GSNO and DEANO 
 NO donors have been chemically synthesized recently and they are grouped based 
on the structure of the NO-releasing moiety. The most widely used NO donors are 
diazeniumdiolates, such as diethylamine NONOate (DEA/NO) (71). They are true NO–
donors, which release a predictable amount of NO (Scheme 3(B)). The second type is 
small molecular weight S-nitrosothiols which donate NO
+
 rather than NO. S-
 19 
 
nitrosocysteine and S-nitrosoglutathione (GSNO) both belong to this class. The third type 
of NO donor is nitrite (Scheme 3(A)). Nitrite releases NO
+
 in a reductive environment. 
The fourth type of NO donor is oxadiazole-N-oxide (72), which is a thiol dependent 
heterocyclic compounds considered as NO releasing prodrugs (73). 
 
A   
B  
Scheme 3: (A) Mechanism of NO release from from DEA/NO. (B) The reaction of 
GSNO releases NO.. 
 
 
 
1.4.5 NO and H2S Interaction – The “Cross Talk” between NO and H2S 
 A plethora of recent evidence shows that the two signaling molecules, NO and 
H2S interact with each other. In the brain, NO donors reportedly modify CBS, causing an 
increase in its activity (14). In human recombinant CBS, NO can bind to the heme group 
which leads to a lowered enzyme activity (48). In the rat aorta, NO donors increase CSE-
dependent H2S biogenesis in a cGMP-dependent manner. Furthermore, pre-incubating 
NO donors increases CSE mRNA and protein levels in smooth muscle cells, which will 
ultimately result in increased H2S production (8,14,54,61). Additionally, LPS-induced 
NO production is associated with increased plasma H2S concentration and H2S 
synthesizing activity in human cells and tissues (10).  
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1.4.6 S-Nitrosylation 
 Protein S-nitrosylation refers to the reaction of a cysteine thiol group with NO in 
the presence of an electron acceptor, oxygen, to form a covalent S-NO bond. In 
mammalian tissues, the S-nitrosothiol (RSNO) concentration varies from nM to μM. 
Endogeneously, S-nitrosylation occurs between the sulfur atom from cysteine or 
homocysteine and NO. The mechanism of an S-nitrosylation is an electrophilic attack of 
a NO
+
 equivalent to sulfur and is followed by deprotonation of thiol group. It is also 
possible that the NO
-
 equivalents attack the electropositive cysteine groups (74). Both of 
the mechanisms are believed plausible. The S-nitrosylation reaction is believed to be a 
third order reaction, the mechanism of which is shown in Scheme 4. The synthesis 
process, transportation, activation and catabolism of RSNO are thought to be regulated 
(75). Evidence illustrates that there is a specific enzyme that catalyzes this reaction and 
only specific thiols from a protein can be targeted to form RSNO. For example, 
ceruloplasmin, a copper-carrying protein in the blood, catalyzes low molecular weight 
RSNO, such as GSNO. Hemoglobin can also serve as an enzyme that catalyzes RSNO 
formation (74,76). Recently, the smallest S-nitrosothiol, HSNO, resulting from the 
reaction of H2S with NO has been identified and proposed to regulate the physiological 
effects of both NO and H2S (77).  
 S-nitrosylation results in special physiological or pathophysiological activity by 
modifying protein function. Some proteins’ activity is increased by s-nitrosylation 
modification, such as thioredoxin, while others may be inhibited, such as methionine 
adenosyl transferase. In some extreme cases, S-nitrosylation abolishes the catalytic 
activity of a protein, such as GAPDH (30). In most cases, nitrosylation inhibits enzyme 
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and receptor activity. This supports the idea that cysteine thiols which are nitrosylated are 
critical for enzymatic activity.  
 One of the widely used methods in identifying RSNO is to use the biotin switch 
assay. In the biotin switch assay, free thiols in the proteins are blocked by a sulfhydryl-
reactive compound, methyl methanethiosulfonate. Then, thiols are exposed to ascorbate 
and labeled with biotin, which are then coupled to streptavidin. Finally, the S-nitrosylated 
proteins are separated by gel electrophoresis (30).  Sometimes, the cell permeable thiol-
alkylating agent, iodoacetamide is used to react with thiol proteins and small molecules, 
glutathionine, cysteine and H2S to block thiols (78). One of the new methods is to use 
gold nanoparticles to isolate thiol-containing peptides to identify SNO (79). 
 
 
Scheme 4: Proposed NO S-nitrosylation mechanism 
 
1.5 RAW 264.7 Macrophages 
 Macrophages are a heterogeneous population of mononuclear phagocytes found 
in the body. These cells are vital for the immunity in response to microorganisms and 
inflammation (80). RAW 264.7 cells are a macrophage-like cell line derived from mice. 
This cell line has the ability to synthesize both NO and H2S. The literature states that the 
H2S-production rate in RAW 264.7 cell is 0.04882 nmol·S
-1
·mg·protein
-1
 (70). 
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Macrophages are the major cellular targets for LPS. Both NO and H2S production rates 
can be enhanced by LPS treatment (70). Since the Western blots do not show the 
expression of CBS, the source of H2S from RAW 264.7 is likely entirely from CSE alone 
(80). One of the beneficial functions of using this cell line is that it can survive in higher 
than physiological H2S concentrations for a long period of time compared with other cell 
lines (68). In view of these properties, RAW 264.7 cells are ideal for studying the 
interplay between NO and H2S signaling in a cellular setting. 
 
 
 
1.6 Summary and Purpose of the study 
 As discussed above, information regarding H2S is still not fully understood. The 
first issue required to assess is the lack of a reliable assay for H2S. An accurate and 
specific detection method would allow us to kinetically characterize enzymatic catalysis 
as well as assess the actual H2S concentrations under controlled conditions. In addition, 
many of the biological effects that have been found for H2S are controversial. The main 
reason for the contentious results is due to many of the studies being carried out with 
indirect measurement of H2S using thiosulfate or sulfhemoglobin. Indirect measurement 
could cause the overestimation or underestimation of the actual H2S concentration. Thus, 
a proper method of H2S assay is required.  
Therefore, this study is aimed at finding an accurate and continuous method for 
the measurement for H2S. Here a simple method based on the selective permeability of 
 23 
 
polydimethylsiloxane (PDMS) to free H2S was developed. The new H2S assay was then 
employed to test the effect of NO and NO donors on the H2S-producing enzymes CSE 
and CBS as well as studying the effects of NO on the cellular production of H2S. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials  
2.1.1 Materials 
Recombinant human CSE (polymorphic variant S403) pET22b plasmid was 
generously provided by Dr. Ruma Banerjee (University of Michigan Medical Center, 
Michigan, USA). Recombinant Zebrafish CBS was obtained from Addgene. Tryptone, 
and yeast extract were purchased from Bio Basic Inc. Potassium phosphate dibasic, 
potassium phosphate monobasic, Tris-HCl, and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid were obtained from Fisher Scientific. EDTA, Lysozyme, 
DNase I, phenylmethanesulfonylfluoride, Isopropyl β-D-1-thiogalactopyranoside, Triton 
X100, His-Select Nickel Affinity Gel, Kanamycin, chloramphenicol, imidazole, 5,5′-
Dithiobis-(2-nitrobenzoate), cysteine hydrochloride, lipopolysaccharide, Nω-nitro-L-
arginine methyl ester hydrochloride, DL-propargylglycine, glutathione, soldium nitrite, 
diethylamine NONOate, homocysteine and pyridoxal-5′-phosphate were all purchased 
from Sigma Aldrich. Polydimethylsiloxane (PDMS) Sylgard 184 Silicone Elastomer Kit 
was purchased from Dow Corning (Cat#3097358-1004). Sodium sulfide nonahydrate was 
purchased from MP Biomedicals. RAW 264.7 macrophages and Dulbecco’s Modified 
Eagle Medium were obtained from ATCC. Fetal Bovine Serum was purchased from 
Invitrogen. Penicillin and Streptomycin were purchased from GIBCO. Zeba
TM
 spin 
desalting columns were obtained from Thermo Scientific. 
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2.1.2 Equipment 
-Amicon centrifugal filter tubes; EMD Millipore, Billerica, MA, USA 
-Centrifuge Jouan BR4i; Thermo Electron Corporation, Asheville, NC, USA 
-C25 Incubator Shaker; New Brunswick Scientific, Enfield, CT, USA  
-Model 100 Sonic Dismembrator; Fisher Scientific, Ottawa, ON, Canada 
-Agilent 8543 UV-VIS Spectrophotometer, Agilent Technologies, Inc. Mississauga, ON, 
Canada 
-Mettler AJ Balance; Mettler, Toledo, Mississauga, ON, Canada 
-Orion Model 420A pH Meter, Thermo Electron Corp., Burlington, ON, Canada 
-Type 37900 Culture Incubator, PGC Scientifics, Palm desert, CA, USA 
-Wallac 1420 Victor 3 Fluorescent Plate Reader, Perkin Elmer, Woodbridge, ON Canada 
-Haemocytometer, Reichert Co, Buffalo, NY, USA 
-SDS-PAGE gel apparatus, Bio-rad, Mississauga, ON, Canada 
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2.2 Methods 
2.2.1 Purification of CBS and CSE 
CSE was purified according to the method of Steegborn et al. (81), but with some 
modifications. Human Histidine-tagged cystathionine gamma-lyase was expressed in E. 
coli XL1B using an expression plasmid generously provided by Dr. Ruma Banerjee (The 
cloning of the CSE and CBS gene was done by Dr. Sirinart Ananvoranich.). Cells were 
grown in 1 L of Terrific Broth using kanamycin and chloramphenicol as the antibiotics 
until the OD600 reading was between 0.4 and 0.6. Expression was induced by addition of 
1 mM isopropyl-β-D-thiogalacto-pyranoside at 37 °C, and the cells were further incubated 
for 4 h. Cells were then collected by centrifugation at 6000 rpm for 30 min at 4 °C The 
cell pellet was resuspended in 20 mL of lysis buffer which contained 100 mM NaCl, 50 
mM Tris-HCl (pH 8.0), 2 mM EDTA, 100 μg/mL lysozyme, 50 μg/mL DNase I, 2 mM 
PMSF (in isopropanol), and 1% Triton x100. The resuspended cells were then incubated 
on ice for 30 min and sonicated using the tip of a Sonic Dismembrator at level 6 for 8 
pulses, with 20 s per pulse. The lysate was then centrifuged at 10 000 rpm for 30 min at 4 
°C. The supernatant was collected and added to a His-Select Ni-Affinity column (Sigma-
Aldrich) equilibrated with 10 mM imidazole in 50 mM Tris-HCl pH 8.0. Elution was 
achieved using 250 mM imidazole in 50 mM Tris-HCl pH 8.0. The collected fractions 
were pooled together and dialyzed overnight against 100 mM HEPES buffer at pH 7.4. 
After dialysis, the enzyme was concentrated by centrifugation at 4 °C for 1 h at 3500 rpm 
in an Amicon centrifugal filter tube. After several spins, ~1mL of the protein was left in 
the column. The concentrated CSE was obtained and stored at −80 °C. Protein 
concentration was determined using the BCA protein assay with bovine serum albumin as 
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the standard. The enzyme purity was then assessed by SDS-PAGE with coomassie blue 
staining. Enzyme activity was determined by monitoring the reaction of DTNB with 
cysteine and H2S produced from the catalytic consumption of cystathionine by CSE at 
405 nm in plate reader. CBS was purified and concentrated using the same procedures. 
2.2.2 Fabrication of the PDMS wells  
 The curing agent was mixed thoroughly using the volumetric ratio of 0.08 to 
monomer to make PDMS. The mixture was degassed using the vacuum of lyophilizer. 
Both parts of the molds were sprayed with a silicone-based lubricant and then the female 
part was filled with ~4mL of the degassed PDMS mixture. The top portion of the mold 
was clamped into the male part using a 2 in. metal C-clamp. The assembly was incubated 
at 70 ˚C for at least 2 h. The assembly was allowed to cool down and was carefully pried 
apart. The solid PDMS polymer was removed from the male portion and was rinsed with 
distilled water, followed by drying at room temperature (Figure 2.1). 
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Figure 2.1 Representative diagrams of the PDMS well assembly mold. The male portion 
(A) was fabricated from Teflon and the female portion (B) was made from aluminum. 
Both parts were sprayed with a silicone-based lubricant. The aluminum part was filled 
with ~4mL of PDMS and the Teflon was placed on top of it. The assembled mold was 
clamped and baked at ~70 °C for at least 2 h. After the mold was cooled, the PDMS wells 
(C) were removed from the mold and rinsed with distilled water. 
 
 
 
 
2.2.3 H2S measurement using cuvette- or plate-based method  
 The buffer used in this study was 0.1 M sodium phosphate (pH 7.4) with 2 mM 
EDTA and all solutions were degassed by stirring and sonicating under vacuum for 1 h, 
followed by purging with argon while stirring for 2 h. Two methods were developed to 
measure H2S production, which are using cuvette or using the plate. In the cuvette-based 
assay (Figure 2.2 A), H2S measurement was done by using the thiol probe DTNB and 
spectrophotometer equipped with a thermostat. This measurement was set up by placing 
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the H2S sources in the PDMS well, which was floating on 1.6 mL of 50 μM DTNB in a 
cuvette containing a stirring bar. For this method, H2S concentrations were calculated 
using the extinction coefficient of the NTB
2-
 anion (ε412 = 14 150M
-1
 cm
-1
). In the plate-
based procedure (Figure 2.2 B), 140 μL of the H2S source was placed into the wells of 
96-well plate. PDMS wells, which contained DTNB (100 μL, 50 μM) were then placed 
into the 96-well plate overtop the H2S source. The PDMS wells were inserted in to the 
plate within 20 s between the sample addition and acquisition. Absorbance at 405 nm was 
measured using a plate reader. For the plate-based procedure, H2S concentrations were 
calculated using a standard curve with Na2S and the appropriate acid dissociation 
constants (Henderson – Hasselbalch). The sample volume required for each method was 
comparable: 20 – 100 μL for the cuvette-based procedure and 140 ± 20 μL for the plate-
based procedure. 
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Figure 2.2 Schemes of the two experimental setups representing the cuvette- and plate-
based PDMS H2S assay. (A) In the cuvette based method, DTNB was placed in the 
cuvette with a stirring bar. The PDMS containing the H2S source floated on top. 
Absorbance at 412 was measured using a UV/Vis spectrophotometer, and free H2S 
concentration was determined using the extinction coefficient for NTB
2−
. (B) In the plate-
based procedure, 140 μL of the H2S source was placed into the wells of 96-well plate. 
PDMS wells that contained DTNB were then placed into the 96-well plate over top of the 
H2S sources. The PDMS wells were inserted i to the plate within 20 s between the sample 
addition and addition. Absorbance at 405 nm was taken using a plate reader. 
 
 
 
2.2.4 Measurement of H2S Production by Purified CSE  and CBS by the Cuvette-
Based Method 
 All solutions were prepared in 0.1 M sodium phosphate buffer (pH 7.4) with 2 
mM EDTA and all of the measurements were taken at 37 °C. H2S produced by CBS and 
CSE on different substrates was examined by measuring the absorbance of NTB
2-
, which 
results from the cleavage of the disulfide bond of DTNB by H2S. PLP with a final of 50 
μM was premixed with 1.4 μM CSE. 160 mM stock solutions of each substrate were 
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made and diluted to various concentrations ranging from 2 to 60 mM in phosphate buffer. 
The substrate was added into PDMS wells before measurement, which was floating in a 
cuvette which contained 1.6 mL of 50 μM DTNB and a stir bar. The floating PDMS cup 
was checked not to block the light path of the spectrophotometer. The cuvette was placed 
into the spectrophotometer, thermostated at 37 ˚C and stirred at 175 rpm, and was 
allowed to thermally equilibrate for 2 min before acquisition. The measurement at 412 
nm was done at 20 s intervals for a total of 1000 s. After the background measurement of 
DTNB was stable after 100 s, the mixture of PLP and CSE was added to the PDMS cup 
with a final volume of 80 μL containing 5 μg of purified CSE. Each sample rate was 
obtained by calculating the linear slope after the slope for the 100 s prior to adding CSE. 
The extinction coefficient used for NTB
2- 
was 14 150 M
-1
 cm
-1
. The detection of the H2S 
produced by CBS used the same procedure. 
2.2.5 Synthesis of S-nitrosoglutathione  
GSNO was synthesized by dissolving glutathione in 0.1 M HCl in a beaker. In 
another beaker, an equimolar amount of sodium nitrite was dissolved in H2O. Dissolved 
sodium nitrite was then added to the acidic glutathione solution while stirring vigorously. 
After the solution turned red, it was kept stirring for another 5 min in the dark. Then, the 
pH of the solution was adjusted to ~7.0 by adding 95% NaOH. The solution was 
lyophilized to obtain the GSNO. 
2.2.6 Mammalian cell culture and treatment 
 RAW264.7 macrophages were kept in a humidified incubator at 37˚C which was 
maintained in a 5% CO2 environment. Dulbecco’s modified Eagle medium was mixed 
with 10% heat-inactivated fetal bovine serum (100 U/mL), penicillin and streptomycin 
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(100 μg/mL) before using it. The treatments were added when cells were at 70-80% 
confluency.  LPS stock solution was prepared by dissolving it in DMSO and then it was 
diluted with DMEM to a final concentration of 4 mg/mL. 2.5 μL of the stock solution 
was added to 10mL of media of the cell culture to a final concentration of 1 μg/mL and 
incubated at 37˚C with 5% CO2 for 12h. Stocks of L-NAME were prepared in DMSO at 
a concentration of 160mM and added to the cells at a final concentration of 4 mM. 
Samples treated with both LPS and L-NAME were treated first with LPS. The cells were 
then washed twice with media and incubated for another 12 h with or without L-NAME. 
2.2.7 Effects of DEA/NO on CSE activity 
 All of the solutions were made using 100 mM phosphate buffer with 0.2 mM 
EDTA at pH 8.0. All measurements were taken at 37 °C. After purification, an aliquot of 
CSE was transferred to speta-sealed vial and was purged with either 2 ppm or 16 ppm 
oxygen with moisture for 40 min on ice. The following steps were done in dark to 
prevent the photodecomposition of S-nitrosylated proteins. DEA/NO was dissolved in 
phosphate buffer and added to CSE with a final concentration of 1 µM. The mixture was 
covered with aluminum foil and agitated for 90 min at 4 °C. Then, the solution containing 
CSE was buffer exchanged using the Zeba
TM
 spin desalting column with phosphate 
buffer to eliminate excess DEA/NO. The buffer exchanged CSE concentration was 
measured using the BCA protein assay. PLP at a final concentration of 50 μM was 
premixed with 1.4 μM CSE in buffer and the mixture was separated into aliquots, and 
each fraction was frozen in the dark before use. The influence of NO on CSE was 
assayed using the same cuvette-based PDMS method as described above. 160 mM of 
cysteine solution was diluted with buffer in different concentrations and incubated for 2 
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min at 37 °C. The substrate in buffer was added to the PDMS wells before each 
measurement. The PDMS wells were then placed in to a cuvette which contained 1.6 mL 
of 50 μM DTNB and a stir bar. The measurement at 412 nm was done at 20 s intervals 
for a total of 1000 s. After 120 s, the background was stable, treated CSE was added. The 
extinction coefficient used for NTB
2- 
was 14 150 M
-1
 cm
-1
. 
2.2.8 Effects of GSNO on CSE 
 Effects of GSNO on CSE were assessed using the cuvette-based PDMS method as 
described for the DEA/NO effects on CSE.  All of the solutions were made using 100 
mM phosphate buffer with 0.2 mM EDTA at pH 8.0 and all measurement was taken at 37 
°C. The exception is that GSNO is a fast NO
+
 donor, hence it was incubated with CSE in 
dark in 10 min before the buffer exchange. In addition, various of GSNO concentrations 
(0.5 µM, 1 µM, 10 µM, 20 µM, 40 µM, 50 µM) were incubated with CSE after 
incubation with either 2 ppm or 16 ppm oxygen. 
2.2.9 Statistical analysis 
 All data are expressed as the mean ± the standard error of the mean. The kinetic 
parameters for initial rate of CSE and CBS producing H2S, KM, Vmax, and Kcat results 
were calculated using the fitted curve of Michaelis-Menten equation.  
 For the DEA/NO and GSNO effect on CSE under 2 ppm or 16 ppm oxygen, 
KM, Vmax, and Kcat/KM of CSE production of H2S using cysteine were determined. Data 
were fitted using the Michaelis-Menten equation. The comparison between the controls 
(without NO donor) and the treated (with NO donor) were compared using the 
student’s t-test. A p-value <0.05 was considered significant  (82).  
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CHAPTER 3 
RESULTS 
3.1 Purification of CBS and CSE 
CSE purification: Recombinant His-tagged human CSE was purified by a 
combination of Ni-affinity chromatography (Sigma-Aldrich) and gel filtration 
chromatography (Sigma-Aldrich). All fractions were tested for cysteine/H2S production, 
using cystathionine as the substrate. The fractions with activity were pooled and 
concentrated. From the purification Table 3.1, the enzyme was purified 2.45-fold with the 
Ni column and appeared as the band with a molecular weight of ~45 kDa (expected 
molecular weight ~47.7 kDa) in SDS-PAGE (Figure 3.1 lane 2). This Ni-column eluate 
was further purified by gel filtration (G-25) (Figure 3.1 lanes 3 and 4). Gel filtration 
activity was increased 1.35-fold. The typical yield of CSE was ~0.95 mg of protein/liter 
of culture (3.31-fold increase in specific activity with respect to crude-Table 3.1).   
CBS purification: Recombinant His-tagged zebrafish CBS was purified by a 
combination of Ni-affinity chromatography (Sigma-Adrich) and gel filtration 
chromatography (Sigma-Adrich). All fractions were tested for Cysteine/H2S production, 
with cystathionine as the substrate. The fractions with activity were pooled and 
concentrated. From the purification Table 3.2, the enzyme was purified 1.59-fold with the 
Ni column and appeared as the band with molecular weight of ~70 kDa (expected 
molecular weight ~68 kDa) in SDS-PAGE (Figure 3.2 lane 2, 3 and 4). This Ni-column 
eluate was further purified by gel filtration (G-25) (Figure 3.2 lane 5). Gel filtration 
activity was increased activity by 1.91-fold. The yield of CBS was ~0.8 mg of 
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protein/liter of culture (3.04-fold increase in specific activity with respect to crude-Table 
3.2). 
 
 
 
 
Table 3.1 Purification table of his-tagged human recombinant CSE expressed in E. coli 
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Table 3.2 Purification table of his-tagged human recombinant CBS expressed in E. coli 
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Figure 3.1 SDS-PAGE of CSE at different purification stages. Lane 1: protein ladder. 
Lane 2: CSE after Ni-affinity chromatography Lane 3 and Lane 4: CSE after gel filtration 
chromatography 
 
Figure 3.2 SDS-PAGE of CBS at different purification stages. Lane 1: protein ladder. 
Lane 2, Lane 3 and Lane 4: CBS after Ni-affinity chromatography Lane 5: CBS after gel 
filtration chromatography 
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3.2 The standard curve of H2S obtained using PDMS wells  
 The standard curve (Figure 3.3) of H2S was obtained using the PDMS-
permeability method for quantifying H2S. The production curve was measured using the 
cuvette-based procedure at pH 7.4, 37 °C. The concentration of solution sulfide generated 
by free H2S diffusion across the PDMS membrane was calculated using the extinction 
coefficient for the NTB
2-
 anion. The permeability rate-based standard curve was linear 
through ~2 orders of magnitude with a detection limit of 13.5 ± 5.3 ppb (m) (parts per 
billion (by mole))/min (or 0.75 ± 0.29 μM/min in 1.6 mL of buffer) free H2S as solution 
sulfide. Rate was calculated within 2 min of sulfide addition to the PDMS well. The 
measurement was stopped at 3 min and this data was used to generate a standard curve in 
the physiologically relevant region of sulfide concentrations.  The detection limit 
estimated from the end point titration is 9.2 ± 1.9ppb (m) (or 0.51 ± 0.10 µM in 1.6 mL 
of buffer) free H2S as sulfide in solution. 
 
 
 
 
 39 
 
 
Figure 3.3 H2S released by H2S donor Na2S measured using DTNB and the cuvette-based 
method. (A) Diffusion rate of H2S across PDMS-membrane produced by various 
concentrations of Na2S. (B) Standard curve calculated from the initial rates of (A). 
  
 40 
 
3.3 Kinetics of H2S production by CBS and CSE using the PDMS method   
 In the interest of validating the cuvette-based method, we continuously monitored 
H2S release from recombinant CSE and CBS as a function of substrate concentration 
using cysteine, homocysteine or cystathionine. As can be seen from the representative 
kinetic plots of vo versus [Cys], and [HCys] of CSE and CBS (Figure 3.4), the data 
displayed saturation kinetics. The vo vs. [substrate] data was fit to the Michaelis-Menten 
equation. The steady state kinetic parameters (KM, Vmax, and Kcat) were estimated from 
the fitted curve (Table 3.3 and Table 3.4). The KM values of CSE catalytic reaction using 
cysteine and homocysteine were compared with the literature values obtained using the 
lead acetate attraction method. The KM determined for cysteine 3.98 ± 2.44 mM, which is 
comparable to the literature value 2.75 mM. The KM for homocysteine was 7.87 ± 4.75, 
which is ~3 times that of the literature value. The KM values of CBS for cysteine and 
homocysteine are 9.39 ± 1.35 and 7.21 ± 1.18, respectively. 
 
Table 3.3 Kinetic parameters of CSE catalysis. The result was determined using PDMS 
cuvette-based method. The KM values in brackets are literature values obtained using Pb-
precipitation H2S assay. 
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Table 3.4 Kinetic parameters of CBS catalysis. Results were determined using the PDMS 
cuvette-based method.  
 
 
 
 
 
 
Figure 3.4 Representative data fitted to the Michaelis-Menten equation. (A), and (B) are 
the initial rates (vo) of CSE-catalyzed H2S formation as a function of [HCys], and [Cys], 
respectively. (C) and (D) are the initial rates (vo) of CBS-catalyzed H2S formation as a 
function of [HCys] and [Cys], respectively. 
 
CSE CBS 
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3.4 The use of the PDMS method to study the effect of Nitric Oxide on CSE 
activity 
In these experiments, CSE was exposed to the NO donor, DEA/NO, for 90 min, in 
the presence of 2 ppm or 16 ppm oxygen. The enzyme solution was passed through a 
desalting column (Thermo Scientific) to remove any NOx ions that might have formed 
during the incubation period. A control CSE fraction was identically treated with varying 
oxygen concentrations, but without DEA/NO. A constant amount of control and NO-
exposed CSE (~1.4 µM) were exposed to varying amounts of Cys. The amount of H2S 
produced was continuously measured by the PDMS method (Faccenda, Wang et al. 
2012). Representative plots and kinetic parameters are shown in Figure 3.5. The KM 
(binding affinity) values of control were compared with the literature values. In the 2 
ppm oxygen control, the KM value for cysteine was 7.27 mM, which is ~2.6-fold higher 
than the literature value (2.75 mM). In 16 ppm oxygen control, the KM value for cysteine 
is 4.42 mM, which is ~1.6-fold higher than the literature value (2.75 mM). The 
differences in KM values are likely due to the different methods used. The literature 
values used lead acetate-based method to monitor the formation of lead sulfide from H2S. 
The heavy metal ion and protein interactions may cause artificial catalytic effects, which 
may result in a lower KM value.  
The kinetic parameters of DEA/NO-treated CSE were then compared with control 
CSE values. At 2 ppm oxygen environment using cysteine, control and DEA/NO-treated 
kinetic parameters were compared. KM showed a ~2.4-fold increase (Figure 3.5 (B)), and 
Vmax of CSE was found to increased of 1.3-fold after treatment with DEA/NO (Figure 3.5 
(C)). Therefore, Kcat/KM decreased ~1.7-fold (Figure 3.5 (D)). With DEA/NO incubation 
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under 16 ppm oxygen using cysteine, KM increased ~1.5-fold (Figure 3.5 (F)) and Vmax 
decreased ~2.3-fold (Figure 3.5 (G)), which attenuated the Kcat/KM of CSE ~3-fold 
(Figure 3.5 (H)). It is interesting that the increase in KM at 2 ppm (~2.4-fold) is higher 
than the increase in KM at 16 ppm oxygen (~1.5-fold), which indicates different reaction 
mechanisms of NO with thiol in low oxygen versus high oxygen environments. 
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Figure 3.5 DEA/NO-treated CSE under 2 ppm or 16 ppm oxygen. The enzyme solution 
was measured for H2S kinetics using the PDMS cuvette-based method. Reactions were 
maintained at 37 ˚C and the CSE concentration in each reaction is ~1.4 μM. (A) 
Representative plot of the initial rate (vo) of CSE (purged with 2 ppm oxygen and 
incubated with or without 0.1 μM DEA/NO) catalyzed H2S formation as a function of 
[Cys]. (B) The binding affinity substrate concentration of maximum velocity (Vmax) of 
control and NO donor treated CSE with 2 ppm oxygen with Cys. (D) The substrate 
concentration of catalytic efficiency (Kcat/KM) of control and NO donor treated CSE with 
2 ppm oxygen with Cys. (E) Representative plot of the initial rate (vo) of CSE (purged 
with 16 ppm oxygen and incubated with or without 0.1 μM DEA/NO) catalyzed H2S 
formation as a function of [Cys]. (F) The binding affinity (KM) of control and NO donor 
treated CSE with 16 ppm oxygen with Cys. (G) The substrate concentration of maximum 
velocity (Vmax) of control and NO donor treated CSE with 16 ppm oxygen with Cys. (H) 
The substrate concentration of catalytic efficiency (Kcat/KM) of control and NO donor 
treated CSE with 16 ppm oxygen with Cys. Errors bars represented standard deviation (n 
= 6). (I) Summarized table of kinetic parameters KM, Vmax and Kcat/KM. 
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3.5 Effects of GSNO on CSE 
 After purging with 2 ppm or 16 ppm oxygen, CSE was exposed to various 
concentrations of GSNO (0.5, 1, 10, 20, and 50 µM) for 10 min. The CSE solution was 
passed through a buffer exchange column (Thermo Scientific) to remove any NOx ions 
that might have formed during the incubation period. A control CSE fraction was 
identically treated with 2 ppm or 16 ppm oxygen concentrations, but without GSNO. A 
constant amount of control and NO-exposed CSE (~1.4 µM) were exposed to varying 
amounts of Cys. The amount of H2S produced continuously was measured by PDMS 
method (Faccenda, Wang et al. 2012). Kinetic parameters are shown in Figure 3.6. In the 
presence of 2 ppm oxygen, the KM value increased with increasing GSNO concentrations, 
with the maximum increase of ~1.8-fold at 20 µM GSNO (Figure 3.6 (B)). This 
illustrates that the binding affinity has decreased. Vmax did not have significant change 
upon incubation of CSE with GSNO (Figure 3.6 (C)). Kcat/KM values decreased with 
increasing GSNO concentrations and the largest decrease in Kcat/KM was ~1.7-fold at 50 
µM (Figure 3.6 (D)). At 16 ppm oxygen, a similar pattern with KM, Vmax and Kcat/KM was 
observed. KM values increased with the increasing GSNO concentration with the 
maximum increase at 50 μM GSNO (~2.1 fold) (Figure 3.6 (F)), also indicats a lowering 
in the binding affinity of the substrate. Vmax values did not change significantly (Figure 
3.6 (G)). As a result, Kcat/KM has a decreasing trend with maximum of ~1.7-fold decrease 
at 50 μM GSNO (Figure 3.6 (H)). When comparing the 2 ppm and 16 ppm conditions, 
the increases in the KM values were similar (~1.8- and ~2.1-fold, respectively). These 
results signify that oxygen in this situation does not affect the interaction of NO with 
CSE. The lowered Cys binding affinity is thought to result from the direct S-nitrosylation 
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of enzyme thiols, thus resulting in the observed alterations in the catalytic efficiency of 
the enzyme. 
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Figure 3.6 H2S production of GSNO-treated CSE under 2ppm or 16 ppm of oxygen. The 
enzyme was measured for H2S kinetics using the PDMS cuvette-based method. Reactions 
were maintained at 37 ˚C and the CSE concentration in each reaction is ~1.4 μM. (A) 
Representative plot of the initial rate (vo) of CSE (which was purged at 2 ppm oxygen 
and incubated with 50 μM GSNO) catalyzed H2S formation as a function of [Cys]. (B) 
The binding affinity (KM) of control and GSNO-treated CSE at 2 ppm oxygen with Cys. 
(C) The substrate concentration of maximum velocity (Vmax) of control and NO donor 
treated CSE with 2 ppm oxygen with Cys.  (D) The substrate concentration of catalytic 
efficiency (Kcat/KM) of control and NO donor treated CSE with 2 ppm oxygen with Cys.  
(E) Representative plot of the initial rate (vo) of CSE (which was purged at 16 ppm 
oxygen and incubated with 50 μM GSNO) catalyzed H2S formation as a function of 
[Cys]. (F) The binding affinity (KM) of control and GSNO-treated CSE at 2 ppm oxygen 
with Cys. (G) The substrate concentration of maximum velocity (Vmax) of control and NO 
donor treated CSE with 16 ppm oxygen with Cys. (H) The substrate concentration of 
catalytic efficiency (Kcat/KM) of control and NO donor treated CSE with 16 ppm oxygen 
with Cys. Errors bars represent standard deviation (n = 3). (I) Summarized table of 
kinetic parameters 
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3.6 NO effects on H2S production of RAW 264.7 cells 
 The PDMS-permeability method was used for the detection of H2S generated by 
cultured cells. In this study, NO inducer, NOS inhibitor or both were added to 
suspensions of RAW 264.7 macrophages, which were then transferred into individual 
PDMS wells, placed into a cuvette and stirred. The H2S produced by the cells was 
diffused through the PDMS bottom layer and subsequently detected by reacting with 
DTNB at 37˚C. There was no detectable H2S in resting RAW cells. The rate of H2S 
release from LPS-stimulated RAW cells was ~0.09 nmol/min/10
6
 cells (Figure 3.7). 
Using the standard curve obtained by this method (Figure 3.3), this corresponds to ~0.58 
nmol sulfide in 100 μL (5.8 μM sulfide or 1.0 μM free H2S). The subsequent H2S 
production of RAW cells with the NOS inhibitor, L-NAME after LPS stimulation, 
increased ~3.8-fold to ~0.35nmol/min/10
6
 cells or 2.13 nmol (21.3 μM sulfide or 3.83 
μM free H2S). This increased rate of H2S production in the presence of NOS inhibitor 
was decreased ~3.8 fold by the CSE inhibitor PAG. This indicates that the H2S detected 
was produced enzymatically. These results also suggest that the increased NO (or NOx) 
concentration in response to LPS in RAW cells depressed the H2S levels. The reason that 
explains this result is that NO directly reacting with H2S or regulating the H2S synthesis 
pathways.   
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Figure 3.7 Rates of H2S release from RAW 264.7 macrophages. Treated cells (~10
6
) were 
lifted and added to PDMS wells containing PLP (50 µM) and Cysteine (1 mM) and the 
rate of H2S release was determined using the PDMS cuvette-based method. Errors bars 
represent standard deviation (n = 3). 
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CHAPTER 4 
DISCUSSION 
4.1 PDMS-based H2S Assay Method and Assessment 
 The reported biological concentrations of H2S vary from nanomolar to the 
millimolar range (10,83,84). Many different methods were used to obtain these results. 
This has raised questions about the accuracy of measurements, especially for methods 
using H2S–reactive chemical indicators. For example, the high H2S concentrations could 
be due to false detection from other sulfide–containing species, oxidized metabolites of 
H2S, or sulfide released as a result of indirect measurement or the probes may not be 
specific for H2S. The most commonly used chemical probe is zinc acetate for trapping 
H2S, followed by reaction with phenylenediamine, forming ethylene blue as a 
chromogenic indicator for H2S (Scheme 2). These chemicals require reaction with H2S, 
and several other steps of sample manipulation including of the pH environment of the 
reaction (85). 
 Based on the drawbacks of the existing methods, our lab developed the PDMS–
permeability method for H2S assay. The method must have the H2S selectivity to become 
a valid H2S assay. The maximum H2S-permeability rate was found to be 244 ± 13 ppm 
(m)/min (or 7.2 ± 0.4 mM/min) free H2S (detected as aqueous sulfide) from the H2S 
donor Na2S at pH 6.0. At pH 7.4 and pH 8.0 the rates were ~63% and 5.4% of the rate at 
pH of 6.0. Other thiols, such as dithiothreitol and glutathione had ~560-fold and ~750-
fold lower permeability at pH 6.0 and pH 7.0 respectively. This indicates the practicality 
of the PDMS-based method for the specific measurement of H2S gas in biological 
samples. 
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The detection limit of the PDMS-permeability method was estimated and 
expressed as aqueous sulfide, which is 9.2 ± 1.9 ppb(m) (or ∼0.51 μM in 1.6 mL of 
buffer) of free H2S. In comparison with other GC-based methods, it can detect H2S as 
low as 1 ppt to 2 ppb (86,87), which indicates that our method is not the most sensitive 
one. However, our method can detect H2S specifically and continuously, without 
complex sample preparation. Therefore, our method serves as a better choice for the 
inexpensive kinetic measurement of free H2S and does not need specialized equipment.  
A major advantage of the PDMS-based assay is that H2S can be detected 
continuously by using virtually any available colorimetric or fluorimetric thiol-specific 
reagent once it crosses the PDMS-membrane. In addition, in-vivo H2S concentrations in 
the synthesis location and the target cells are different. The location where CSE or CBS is 
producing H2S would obviously have a higher content of H2S compared to the target cells 
which are far away from the H2S synthesizing location and actually consume H2S (84,88). 
The advantage of using the PDMS-based method is detecting H2S at the original 
producing location, before it crosses a membrane, which would provide us knowledge of 
H2S being produced and H2S that is being metabolized. It is known that H2S is produced 
in the cytoplasm and oxidized in the mitochondria (89). Applying this assay by simply 
substituting cellular extract in the place of cellular suspensions may also be of use to 
assess this intracellular H2S production.   
Beside the advantages discussed above, the PDMS-based method does have 
drawbacks. One noticeable disadvantage is the relatively thick (∼100 μM) PDMS 
membrane bottom layer and ∼20 s lag between H2S addition/release and detection 
(Figure 3.3 (A)). Additionally, the thick membrane may prevent some H2S diffusion, thus 
 52 
 
preventing thiols from being detected. Both of these factors could account for the 
detection limit of H2S using this method, however, this issue can be solved by 
manufacturing thinner membranes. 
4.2 Determination of KM and Vmax of CSE and CBS for cysteine and homocysteine  
The PDMS permeability method was used to determine the kinetic parameters of 
recombinant CSE and CBS (Table 3.3 and Table 3.4) and compared with literature values 
where possible. For the kinetic parameters of CSE, the KM determined for cysteine was 
3.98 ± 2.44 mM, which is comparable to the literature value of 2.75 mM (13). The reason 
that may explain the slight difference between the PDMS-measured KM value and the 
literature value is that PDMS method was performed at physiological pH. The literature 
value was assayed at pH 8.2, which is optimal for H2S generation by CSE and CBS. In 
addition, more of the total sulfide will traverse the PDMS membrane as free H2S at pH 
~6 compared to higher pH values. CSE KM value for homocysteine was determined to be 
7.87 ± 4.75 mM. The KM that we detected is almost three times higher than the literature 
value (2.7 ± 0.85 mM) which was tested using a lead acetate-based method with 
spectrophotometry measuring a lead sulfide precipitate. The issue regarding this method 
is that the heavy metal ion (Pb
2+
)−protein interactions may induce the artificial 
overproduction of H2S (90). Zebrafish CBS enzyme kinetic parameters are shown in 
Table 3.4. The binding affinity KM values of CBS for HCys and Cys are 7.21 ± 1.18 mM 
and 9.39 ± 1.35 mM respectively. Zebrafish recombinant CBS has a relatively low 
binding affinity to its substrates compared with human recombinant CSE. The human 
recombinant CBS in literature has a binding affinity of 1.1 ± 0.7 mM for homocysteine. 
Similar to the CSE literature KM value, this kinetic assay also utilized heavy metal to 
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detect H2S. In human CBS, the allosteric effector AdoMet could bind to the CBS domain 
of the protein, hence the reaction rate Vmax increases by ~2 to 3–fold without changing 
the KM (23,32,35). Therefore, the CBS activity could be controlled by modulating this 
allosteric domain. 
4.3 Effects of DEA/NO on recombinant CBS and Effects of DEA/NO and GSNO 
on recombinant CSE 
 As discussed, both NO and H2S could be generated in a biological environment 
and could cross-talk. It has been found that NO could bind to the heme of human CBS 
and inhibit enzyme activity (48). Furthermore, our lab indicates that NO or NOx may 
influence H2S production by regulating H2S-generating enzyme (CBS or CSE) activities 
(91). Hence for the purpose of studying NO’s function of regulating the H2S biosynthesis 
pathway, the effects of DEA/NO and GSNO on CSE in a biological environment were 
examined. DEA/NO is a type of diazeniumdiolate, which has NO covalently connected to 
a diethylamine. GSNO is a nitrosothiol (71) and NO can be spontaneously released (72). 
GSNO is different from DEA/NO. This is because the NO releasing mechanism of 
GSNO (Scheme 3 (A)) is different than for DEA/NO (Scheme 3 (B)). GSNO is reported 
to be a more efficient S-nitrosylating agent compared to DEA/NO (92). Additionally, 
Sinha et al. demonstrated that different chemistries of NO release lead to different 
biological responses (72). Thus, different mechanisms acting on CSE by NO released 
from these two NO donors would be expected. This was examined by mimicking two 
types of physiological environments: 2 ppm and 16 ppm oxygen. 2 ppm oxygen 
represents a hypoxic condition in ischemia/reperfusion injury, and 16 ppm oxygen 
mimics the normal oxygen level in the lung, heart, brain and all tissues. Here the 
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evaluation examined the three parameters: KM, Vmax, and Kcat/KM. The comparisons 
between the control and DEA/NO-treated CSE kinetic parameters were made. At 2 ppm 
or 16 ppm condition with DEA/NO treatment, KM increased ~2.4 or ~2 fold compared 
with control (Figure 3.5), respectively, which indicates the possible structural changes 
induced by NO binding that could lower the Cys binding affinity to CSE. The lowered 
binding affinity subsequently attenuated enzyme activity. Since the KM values changed 
differently at 2 ppm and 16 ppm for DEA/NO treated CSE, a possible reaction 
mechanism may apply to the anaerobic environment, and another possible reaction 
mechanism may apply to aerobic environment. GSNO was also used to check the effects 
of NO on H2S-producing enzyme. H2S production was measured at both 2 ppm and 16 
ppm oxygen with different concentrations of GSNO, ranging from 0.5 to 50 μM. KM 
values have a maximum increase of ~2 fold with increasing concentration of GSNO for 
both 2 ppm and 16 ppm oxygen environment. The similar increase of KM values indicates 
that oxygen may not play a role in the GSNO-treated CSE catalytic reaction. Therefore, 
the modification of GSNO on CSE may follow the NO modification under low oxygen 
level. 
For all of the NO-treated CSE, the most noticeable changes are the lowered 
binding affinity and subsequent depressed catalytic activity. This may be due to the 
reaction of NO with cysteine residues on CSE. There are 10 cysteines on each monomer 
of human recombinant CSE. A few of them are close to the PLP-binding catalytic site. A 
proposed mechanism of direct reaction between nitric oxide and thiols without the 
presence of oxygen may explain this structure change mechanism at 2 ppm oxygen. NO 
can induce disulfide formation (93) (Scheme 5). In this mechanism, NO directly oxidizes 
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thiols to a disulfide: RSSR. This proposed mechanism has been found as a major product 
in RAW cells under low oxygen condition (94). 
In the presence of oxygen (16 ppm), NO may react with oxygen to form ˙NO2, 
and ˙NO2 can react with another NO molecule to produce N2O3 (75). N2O3 could then 
react with the RSH group of cysteine of CSE resulting in the formation of RSNO 
(72,74,75) (Scheme 6). Another potential pathway would be ˙NO2 formed from the 
reaction of ˙NO with oxygen reacts with thiol (RSH) to form a thiyl radical (RS˙), and 
then another ˙NO comes to react with it to form S-nitrosothiols (Zhang, Andrekopoulos et 
al. 2009) (Scheme 6). As a result, the S-nitrosylated cysteine may change the structure or 
folding of the protein, and hence affect the catalytic properties of CSE. S–nitrosylation is 
predicted to occur primarily in the hydrophobic domains of proteins, which is kinetically 
favourable (93). According to Hess et al. and Liu et al., both NO and oxygen are 
hydrophobic, and hence the microenvironment that would support S-nitrosylation should 
be hydrophobic (95,96). Based on findings, we propose that the possible S-nitrosylation 
in CSE should be in its hydrophobic microdomains. Figure 4.1 highlighted the 
hydrophobic domain of CSE, where the possible modification would take place. S-
nitrosothiols formed during from S-nitrosylation have physiological functions which 
could be used in other signaling pathways. In a recently published paper, Filipovic 
reported that a new compound: thionitrous acid (HSNO) could be formed from H2S with 
low molecular weight thiols or S-nitrothiols (Scheme 7), which can freely cross the 
cellular membrane and act as a source of NO and as a transnitrosating agent (77).  
The other way in which NO could affect enzyme activity is the modification of 
tryptophan and tyrosine. NO was found to directly scavenge tyrosine and tryptophan 
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radicals in amino acids, peptides and proteins (97). In the case of the Tyr residue, Tyr˙ 
could react rapidly with nitric oxide derivative, nitrogen dioxide (˙NO2) to form 3-
nitrotyrosine (Scheme 8 A). Alternatively, NO may react with Trp˙ to form N-nitro 
species (Scheme 8 B). One of these two residues may be in the catalytic site or important 
for protein folding, therefore their modification could result in depressed enzyme activity.  
 
Figure 4.1 Highlighted hydrophobic domain of CSE shown in yellow, where S-
nitrosylation may occur. 
 
 
 
Scheme 5: The reaction of NO with thiols in the absence of oxygen  
 
 
 
 
 
Scheme 6: Reactions of NO with thiols in the presence of oxygen 
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Scheme 7: Reactions for the formation of HSNO 
 
 
 
Scheme 8: Reactions of NO with Tyr (A) and Trp (B). 
 
 
 
(A) 
(B) 
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4.4 NO inducer and NO suppresser effects on H2S production in RAW 264.7 cells
 The PDMS-based H2S assay was used to monitor the H2S production from 
stimulated and unstimulated RAW 264.7 cells. LPS is a known NOS inducer which could 
increase the expression of CSE (41,68) and L-NAME is a NOS inhibitor. In this study, 
both the NOS inducer and inhibitor were incubated with RAW cells for 12 h, with the L-
NAME incubation occurring after LPS stimulation. The production of H2S by CSE was 
then measured. Previous studies show that LPS induces NO production by inducing 
iNOS expression. According to the recent work of Zhu et al., LPS stimulation could 
increase H2S production by CSE (27,80), and this activation may depress the NO 
production by interacting with NO equivalents, such as NO
+
 and N2O3 (68). This 
experiment is aimed to test this hypothesis: NOx reacts with H2S. By inhibiting NO 
production using L-NAME, H2S production increased by ~3.8 fold (Figure 3.7). These 
results provide evidence that stimulated NO or NOx production in RAW cells inhibits 
H2S production by either direct reaction with H2S or by interfering with its biogenesis 
pathway. From the study of PDMS with NO in the normal and low levels of oxygen 
environment, it is possible that NO and oxygen are concentrated in the hydrophobic 
PDMS environment, reacting to form N2O3 (91). The latter can readily react with sulfide. 
This phenomenon is expected to happen in the hydrophobic microdomains of cells 
leading to a direct scavenging of H2S. It is also possible that NO or NOx could modulate 
the H2S-producing pathway by directly acting on the activity and expression of CSE and 
CBS as proposed in the NO effects on both enzymes.  
 
 
 59 
 
4.5 The cross-talk between H2S and NO 
 The study of cross-talk between H2S and NO became popular recently, due to the 
evidence of NO and H2S signaling pathways interacting with each other, where one could 
intensify the other’s physiological effect (98) and this study has been focused on 
mechanisms that are not yet fully understood. H2S and NO are known to directly react 
with one another. My study attempted to determine the direct effects of NO donors on 
CSE activity. Results suggest that DEA/NO and GSNO may have a potential role in 
regulating CSE-dependent H2S production by changing the stability and activity of a 
protein (78). The resulting modification: RSNO could be used for further physiological 
purpose, such as regulating enzyme activity by modifying the thiol-dependent process 
(75), control the vascular tone (99), or could be useful for S-nitrosothiol-mediated 
pathways (100). These results suggest that direct NO donor could be a potential 
therapeutic compound for partially inhibiting CSE-dependent H2S production in patients 
who have hyperhomocysteinemia (28). Controlling the release of H2S could also be a 
potential method to attenuate cardiovascular-related disease. Slow NO donors may be 
also useful in controlling H2S-induced inflammation. For example, it has been shown that 
H2S can induce NO production (61), and NO donor inhibits LPS-induced H2S biogenesis 
(101). Therefore, NO and H2S may function to regulate the inflammatory response (45). 
Therefore, managing H2S biosynthesis could be a helpful method to reduce H2S-related 
diseases, but further tests are necessary to determine the amount of NO that is necessary 
to lower H2S production in biological systems. Similarly, H2S donor could control NO 
production. During endotoxic shock, H2S inhibits iNOS expression (102). Thus, these 
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studies provide evidence of the interaction between NO and H2S and investigate the 
potential methods for controlling the concentration of one in the production of the other. 
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CHAPTER 5 
CONCLUSION AND FUTURE WORK  
 H2S and NO are two gaseous molecules which have important roles in regulating 
physiological functions. The evidence shows that the two signaling molecules regulate 
each other in controlling these physiological functions. This project is aimed to study the 
cross talk between NO and H2S. Due to the disadvantages of the existing H2S assays, we 
developed a continuous accurate H2S assay, which uses H2S-selective PDMS-permeable 
membranes. PDMS was molded into wells that can fit into a 96-well plate or a cuvette for 
continuous measurements. The method was validated using H2S-producing enzymes CSE 
and CBS. The resulting kinetic parameters of CSE were compared with the literature 
values and were within the literature range when using cysteine as the substrate. Then, 
this method was used to examine the NO donor effects on H2S-producing enzyme: CSE. 
The lowered binding affinities led to depressed catalytic activities of enzymes. The 
results hint that NO may modify enzyme residues and these residue modifications may 
affect their catalytic efficiency. Further, H2S production by RAW 264.7 macrophages 
was also examined using the PDMS method. The results suggest that stimulated NOx 
inhibits H2S production by either direct reaction with H2S or by interfering with its 
biogenesis pathway. As a result, these studies raise the possibly that NO has the potential 
to regulate H2S production.  
 Future work involves the use of mass spectrometry to identify the specific 
residues that are modified by NO. For instance, if the S-nitrosylation is achieved under 
NO treatment, it is important to find which cysteine is being modified. If the modification 
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is not on cysteine, NO would either react with tyrosine or tryptophan residues. Locating 
the modification would allow as to manipulate the H2S production by the enzymes. 
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